Business Context and Reporting Period
This Form 8-K, dated February 3, 2020, reports the consummation of a two-step merger between Cerecor Inc. ("Cerecor") and Aevi Genomic Medicine, Inc. ("Aevi"). The transaction closed on February 3, 2020, with Cerecor retaining its public reporting status and NASDAQ listing (Symbol: CERC). The filing also details the termination of a backstop agreement dated January 31, 2020, and significant changes to the board of directors and executive leadership.
Key Financial Metrics and Transaction Terms
- Merger Consideration: Aevi shareholders received approximately 3.9 million shares of Cerecor common stock (conversion ratio of 0.0334) and one Contingent Value Right (CVR) per share.
- Contingent Value Rights: CVRs represent the right to receive up to $6.5 million in cash or stock upon the achievement of certain milestones.
- Ownership Structure: Post-merger, pre-closing Cerecor shareholders own approximately 93.1% of the company, while former Aevi shareholders own approximately 6.9%.
- Share Count: Approximately 56.3 million shares of Cerecor common stock were outstanding as of February 3, 2020.
- Financial Statements: The filing references audited financial statements for Aevi for 2017 and 2018, and unaudited statements for the nine months ended September 30, 2019. Specific revenue, profit, or cash flow figures for the combined entity are not provided in this text; they are contained in the referenced exhibits.
Material Changes
- Termination of Backstop Agreement: On January 31, 2020, Cerecor terminated a Backstop Agreement with Armistice Capital Master Fund Ltd. No termination penalties were incurred.
- Leadership Changes:
- Board: Increased from seven to nine members. Sol J. Barer, Ph.D., and Michael F. Cola were appointed.
- CEO: Michael F. Cola appointed as Chief Executive Officer.
- CMO: Garry A. Neil, M.D., appointed as Chief Medical Officer.
- Compensation Agreements: New employment agreements were executed for Mr. Cola and Dr. Neil, including base salaries of $450,000 and $410,000 respectively, and significant inducement option grants (1.2 million and 800,000 shares).
- Royalty Assumption: Cerecor assumed a royalty agreement from Aevi involving a $2 million payment to investors (including Mr. Cola and Dr. Neil) in exchange for a low-single digit percentage of net sales of CERC-006.
Outlook, Risks, and Contingencies
- Contingent Payments: The $6.5 million CVR payment is contingent on achieving specific milestones, with payment form (cash or stock) at Cerecor's sole discretion.
- Royalty Buyout: Cerecor retains the option to buy out the royalty agreement obligations three years after the first public launch of the OSI Product for 75% of the net present value of future royalty payments.
- Executive Retention: Employment agreements include change-in-control provisions and severance packages (18 months base salary, full option vesting) if terminated without cause or for good reason.
- Financial Data: The filing text does not provide specific forward-looking guidance, revenue projections, or liquidity metrics for the combined entity beyond the transaction terms.
Investor Verification Checklist
- Verify the specific milestones required to trigger the $6.5 million Contingent Value Rights payment.
- Review the full text of the Royalty Agreement to understand the exact percentage of net sales owed to investors for CERC-006.
- Examine the unaudited pro forma financial statements (Exhibit 99.5) for a detailed view of the combined entity's financial position.
- Confirm the vesting schedules and performance conditions for the 1.2 million options granted to the new CEO and 800,000 options to the new CMO.
- Assess the impact of the new executive compensation structure on future cash burn and dilution.